本帖最后由 老马 于 2013-3-13 13:43 编辑 3 M) l/ A1 V' L, j7 X8 e
' {5 N2 w. R/ a5 z( H3 y健择（吉西他滨）+顺铂+阿瓦斯汀
3 ^) I7 h# v5 S4 b, E Gemzar +Cisplatin + Avastin0 H1 T2 s9 _0 G% j4 w7 R# j
http://annonc.oxfordjournals.org/content/21/9/1804.full+ n8 A% R# Q! f. T5 A5 i
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
/ p. w" ?2 a9 C1 {Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
( M8 j* @5 R7 q# q9 gResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
w4 x* B" S/ c* u5 U: J
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 242)
$ _/ J# I1 U) c& y/ \' E# s华为网盘附件：
6 S$ F7 [1 Y8 o; b! _' |4 ^【华为网盘】ava.JPG7 N0 z! q7 [+ y9 m4 w9 N+ n
|
显身卡
